drugs, such as age, bronchodilator reversibility, and history of or current tobacco use. Naturally, some criteria may be warranted by the trial methodology to reach the primary endpoint. For example, the minimum exacerbation rate in the previous year may guarantee a sufficient number of events to avoid studies being prolonged if the primary endpoint is the time until the first exacerbation. These administrative and financial constraints should not, however, affect the scientific value of these studies, and the results should remain able to be extrapolated to excluded populations.
A Potential Link between Serum Low-Density Lipoproteins and Asthma

To the Editor:
We read with great interest the article by Barochia and colleagues about the relationship between serum lipid and apolipoprotein levels and asthma (1) . As highlighted by the authors, although apolipoproteins and lipoproteins are important modulators of inflammation, varying relationships exist between these parameters and asthma (2) , and the data are still not conclusive. Indeed, it is still not fully clear which lipoproteins are more strictly associated with asthma development and progression (severity).
Barochia and colleagues report a positive correlation between FEV 1 % predicted and high-density lipoprotein (HDL)-cholesterol or apolipoprotein A-I in atopic asthma, and they also suggest that this correlation may be largely mediated by the subfraction of large HDL particles. This finding seems to complement what we In that study, we hypothesized that LDL could represent a potent trigger for the inflammatory changes of the airways. It was somewhat surprising that the Barochia and colleagues did not mention our study, as it still represents the only study that has assessed the full spectrum of all seven LDL subclasses in asthma.
As highlighted by the European Panel on LDL Subclasses (4), the methodology used for assessing lipoprotein subclasses is crucial. In the present study, Barochia and colleagues used nuclear magnetic resonance spectroscopy to assess the lipoprotein particles; yet with this methodology, they were able to assess only a few subclasses with low resolution (e.g., three very-low-density lipoprotein subclasses [large, medium, and small very-low-density lipoprotein], two LDL subclasses [large and small LDL], and three HDL subclasses [large, medium, and small HDL]). Methodologies are available to assess lipoprotein subfractions with a higher degree of resolution, and in our study, we used a methodology of gel electrophoresis (Lipoprint; Quantimetrix Corporation, Redondo Beach, CA) that is able to distinguish seven LDL subclasses (3) as well as 10 HDL subclasses (5) .
Of interest, in our study (3), we reported that asthma was associated with smaller LDL particles, which are proinflammatory particles (6) , and in the present study, Barochia and colleagues reported that asthma was associated with larger HDL particles, which seem to be dysfunctional HDLs with proinflammatory properties (7). We therefore believe that the findings of the two studies support the concept that small LDLs could lead to the amplification of the inflammatory cascade in asthma, and we advocate for larger studies specifically designed to confirm the association between asthma and dyslipidemia and to elucidate the underlying mechanisms. n 
